Adaptimmune is driven by a mission to transform the lives of people with cancer by designing and delivering cell therapies. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cell receptors (TCRs) to target and destroy cancer, including solid tumors.
The Company is preparing for its first biologics license application (BLA) submission of the first-ever engineered TCR T-cell therapy for solid cancer tumors. If approved, this TCR therapy will be used to treat patients with synovial sarcoma, a rare cancer for which there is a high unmet medical need.
Adaptimmune has been purposefully built as an integrated cell therapy company, owning each stage of the development, manufacturing, and commercialization of its SPEAR T-cell therapies for cancer, setting it apart from other biotechnology companies in the field.